| abstract |
The present invention refers to a pharmaceutical combination comprising the synergic combination of a leukotriene-receptor antagonist such as the active principle montelukast and pharmaceutically acceptable salts thereof, and an histamine H1 inverse agonist such as the active principle ketotifen and pharmaceutically acceptable salts thereof, formulated with pharmaceutically acceptable excipients and/or carriers and/or additives, in a single dosing unit to be administered orally, transdermally or in devices for oral or nasal inhalation, indicated for the treatment of an atopic disease such as asthma, allergic rhinitis and atopic dermatitis. |